As of close of business last night, Cognition Therapeutics Inc’s stock clocked out at $1.84, down -6.60% from its previous closing price of $1.97. On the day, 1118936 shares were traded.
Ratios:
To gain a deeper understanding of CGTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.38 and its Current Ratio is at 4.38. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on November 03, 2021, initiated with a Outperform rating and assigned the stock a target price of $22.
On November 03, 2021, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $27.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGTX now has a Market Capitalization of 59.67M and an Enterprise Value of 27.44M.
Stock Price History:
Over the past 52 weeks, CGTX has reached a high of $3.49, while it has fallen to a 52-week low of $0.90. The 50-Day Moving Average of the stock is 2.1150, while the 200-Day Moving Average is calculated to be 1.7582.
Shares Statistics:
It appears that CGTX traded 230.30K shares on average per day over the past three months and 293.01k shares per day over the past ten days. A total of 28.99M shares are outstanding, with a floating share count of 22.04M. Insiders hold about 27.54% of the company’s shares, while institutions hold 21.88% stake in the company. Shares short for CGTX as of Feb 29, 2024 were 126.75k with a Short Ratio of 0.55, compared to 145.42k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.39% and a Short% of Float of 0.59%.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.34 for the current quarter, with a high estimate of -$0.27 and a low estimate of -$0.4, while EPS last year was -$0.2. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.29 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.87 and -$1 for the fiscal current year, implying an average EPS of -$0.95. EPS for the following year is -$1.1, with 3 analysts recommending between -$0.57 and -$1.69.
